The 2026 State of GLP-1 Telehealth

Based on our 100-point scoring of 105 providers, the top-rated platforms vary by category. For brand-name medications, Hims (72/100) and Found (69/100) lead. For compounded semaglutide with verified purity, FormBlends (78/100) and Eden (70/100) score highest. For full clinical programs, FORM Health (72/100) and Calibrate (62/100) offer the most structured approaches.

The true all-in cost averages $347/month for compounded semaglutide and $1,128/month for brand-name medications across 105 providers. Most advertised prices exclude membership fees, consultation charges, lab work, and dose escalation costs. The cheapest compounded options start around $119/month (Henry Meds) but carry regulatory and quality risks.

The FDA issued 85+ warning letters to GLP-1 telehealth sellers between September 2025 and March 2026. Named recipients include Hims and Hers, MEDVi, Bliv Wellness, Belle Health, FitRX, BluefitMD, Viv Health, 24HrDoc, and GoodGirlRx. Common violations include comparing compounded products to FDA-approved drugs and implying telehealth companies compound medications themselves.

Safety varies by source. Novo Nordisk testing found impurity levels up to 86% in some compounded injectable semaglutide and 75% in oral forms. Providers using NABP/PCAB-accredited pharmacies with published third-party Certificates of Analysis (COAs) on every batch offer better quality assurance. The FDA has cracked down on compounders since removing semaglutide from the shortage list in February 2025.

Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro) are FDA-approved with clinical trial data and standardized manufacturing. Compounded versions are mixed by pharmacies using the same active ingredient but without FDA approval for the final product. Compounded medications cost $99-299/month vs $149-599/month for brand-name. The FDA has issued 85+ warning letters to compounded GLP-1 sellers.

Only about 40% of GLP-1 telehealth providers offer dedicated mobile apps. Noom leads with a 4.7/5-rated app featuring AI Face Scan and behavior change curriculum. Hims, Ro, WeightWatchers, Found, and Mochi also have apps. Most compounding-focused providers including FormBlends, Eden, MEDVi, Henry Meds, and ShedRx operate web-only without mobile apps.

Only 19% of large employer health plans covered GLP-1s for weight loss as of January 2026. Medicare Part D coverage begins January 2027, with an early access GLP-1 Bridge program starting July 2026. Zepbound has a Medicare cap of $50/month starting April 2026. Providers like Found, WeightWatchers Clinic, and PlushCare offer the strongest insurance integration.

We identified and scored 105 telehealth providers offering GLP-1 medications for weight loss in the United States as of April 2026. These range from publicly traded platforms like Hims ($2.35B revenue) and Ro ($7B valuation) to single-provider operations. We expect consolidation to reduce this to 30-40 viable operators by 2028.